Article Text

PDF
SAT0302 Analysis of 9302 patients from the big data international primary sjÖgren syndrome cohort: clinical presentation at diagnosis of european vs non-european patients
  1. P Brito-Zerόn1,2,
  2. N Acar-Denizli3,
  3. M Zeher4,
  4. A Rasmussen5,
  5. R Seror6,
  6. T Mandl7,
  7. X Li8,
  8. C Baldini9,
  9. J-E Gottenberg10,
  10. D Danda11,
  11. R Priori12,
  12. L Quartuccio13,
  13. G Hernandez-Molina14,
  14. AA Kruize15,
  15. S-H Park16,
  16. M Kvarnström17,
  17. S Praprotnik18,
  18. D Sene19,
  19. E Bartoloni20,
  20. R Solans21,
  21. Y Suzuki22,
  22. D Isenberg23,
  23. M Rischmueller24,
  24. G Nordmark25,
  25. G Fraile26,
  26. A Sebastian27,
  27. A Vissink28,
  28. T Nakamura29,
  29. V Valim30,
  30. R Giacomelli31,
  31. V Devauchelle-Pensec32,
  32. B Hofauer33,
  33. M Bombardieri34,
  34. V Trevisani35,
  35. D Hammenfors36,
  36. SE Carsons37,
  37. SG Pasoto38,
  38. J Morel39,
  39. S Retamozo40,
  40. TA Gheita41,
  41. F Atzeni42,
  42. C Vollenveider43,
  43. X Mariette6,
  44. M Ramos-Casals2,
  45. on behalf of the EULAR-SS Task Force Big Data Consortium
  1. 1Hosp CIMA-Sanitas
  2. 2Hosp Clínic, Barcelona, Spain
  3. 3Msgsü, Istanbul, Turkey
  4. 4Univ, Debrecen, Hungary
  5. 5OMRF, Oklahoma, United States
  6. 6Univ Paris Sud, Paris, France
  7. 7Lund Univ, Malmö, Sweden
  8. 8Anhui Hosp, Hefei, China
  9. 9Univ, Pisa, Italy
  10. 10Univ, Strasbourg, France
  11. 11CMC, Vellore, India
  12. 12Sapienza Univ, Rome
  13. 13Santa Maria, Udine, Italy
  14. 14INCMNSZ, México City, Mexico
  15. 15UMC, Utrecht, Netherlands
  16. 16Catholic Univ Korea, Seoul, Korea, Republic Of
  17. 17Karolinska Instit, Stockholm, Sweden
  18. 18UMCL, Ljubljana, Slovenia
  19. 19Lariboisière Hosp, Paris, France
  20. 20Univ, Perugia, Italy
  21. 21Hosp Vall d'Hebron, Barcelona, Spain
  22. 22Univ Hosp, Kanazawa, Japan
  23. 23UCL, London, United Kingdom
  24. 24TQEH, Adelaide, Australia
  25. 25Univ, Uppsala, Sweden
  26. 26Hosp Ramόn y Cajal, Madrid, Spain
  27. 27Med Hosp, Wroclaw, Poland
  28. 28Univ, Groningen, Netherlands
  29. 29Univ, Nagasaki, Japan
  30. 30UFES, Vitόria, Brazil
  31. 31Univ, L'Aquila, Italy
  32. 32Univ, Brest, France
  33. 33TUM, München, Germany
  34. 34QMUL, London, United Kingdom
  35. 35UNIFESP, Sao Paulo, Brazil
  36. 36Haukeland Hosp, Bergen, Norway
  37. 37School Med SBU, Mineola, United States
  38. 38USP, Sao Paulo, Brazil
  39. 39Univ, Montpellier, France
  40. 40INICSA, Cordoba, Argentina
  41. 41Univ, Cairo, Egypt
  42. 42L.Sacco Univ, Milan, Italy
  43. 43German Hosp, Buenos Aires, Argentina

Abstract

Objectives Baseline characterization of European patients diagnosed with primary Sjögren syndrome (SS) according to the 2002 AE criteria.

Methods The Big Data Sjögren Project was formed in 2014 to take a “high-definition” picture of the main features of primary SS by merging international SS databases. International experts of the EULAR-SS Task Force were invited to participate. By January 2017, the database included 9302 consecutive patients recruited from 21 countries of the 5 continents.

Results A total of 6586 (71%) patients were included from European countries. In comparison with non-European countries, European patients had a higher mean age (54 v 51yrs, p<0.001), higher frequency of men (7% v 5%, p=0.001), dry eyes (94% vs 88%, p<0.001), dry mouth (94% vs 91%, p<0.001), and lower frequency of abnormal ocular (84 vs 86%, p=0.049) and oral (75 vs 81%, p<0.001) tests. Immunologically, European patients had a lower frequency of anti-Ro/La antibodies (69 vs 78%, p<0.001) and a higher frequency of RF (50 vs 47%, p=0.01), low C4 (14 vs 9%, p<0.001) and cryoglobulins (8% vs 3%, p<0.001). Logistic regression identified as independent variables older age (OR 1.02), male gender (OR 2.62), abnormal oral tests (OR 0.26), anti-Ro/La antibodies (OR 0.69), RF (OR 1.76), low C4 (OR 1.97) and cryoglobulins (OR 3.85).

Conclusions European patients are diagnosed at older age, are more frequently men, and presented a lower frequency of anti-Ro/La antibodies and a higher frequency of immunological markers related to mixed cryoglobulinemia.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.